Antimicrobial composition, antiviral composition, and uses thereof

Abstract

To provide technologies for enhancing the antimicrobial and antiviral effects of silver-bound fucoidan.SOLUTION: Provided are an antimicrobial composition comprising silver-bound fucoidan in which silver is bound to the sulfate group of fucoidan and green tea extract, and an antiviral composition comprising silver-bound fucoidan in which silver is bound to the sulfate group of fucoidan and green tea extract.SELECTED DRAWING: Figure 3

Description

Technical Field

[0001] The present invention relates to an antibacterial composition, an antiviral composition containing silver-bonded fucoidan and green tea extract, and their uses.

Background Art

[0002] Infections caused by bacteria and viruses have a great impact on people's lives. To prevent infections, in addition to humans wearing hygiene products such as masks, it is conceivable to use antibacterial agents, antiviral agents, etc. in places where humans come into contact.

[0003] In addition, drugs used for antibacterial and antiviral purposes so far are used daily, so components that are gentle and safe for the skin, etc. are required.

[0004] The present inventors have been searching for safer antibacterial and antiviral components from natural product-derived components such as those used for food, and fucoidan derived from brown algae has been listed as a candidate. And the present inventors have found that silver-bonded fucoidan obtained by bonding silver to the sulfate group of this fucoidan has excellent antibacterial and antiviral effects, and have filed a patent application (Patent Document 1).

[0005] However, although the above silver-bonded fucoidan has excellent antibacterial and antiviral effects, due to the emergence of new bacteria and resistant bacteria, highly effective ones are always in demand. Therefore, there has been a demand for a technology to further enhance the antibacterial and antiviral effects of silver-bonded fucoidan.

Prior Art Documents

Patent Documents

[0006]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0007] Therefore, an object of the present invention is to provide a silver-bound fucoidan having enhanced antibacterial and antiviral effects.

Means for Solving the Problems

[0008] The inventors of the present invention conducted intensive research to solve the above problems. As a result, they found that by combining a silver-bound fucoidan with a green tea extract, even when the amount of the combined green tea extract alone shows almost no antibacterial or antiviral effect, the excellent antibacterial and antiviral effects of the silver-bound fucoidan can be enhanced, and thus completed the present invention.

[0009] That is, the present invention is an antibacterial composition characterized by containing a silver-bound fucoidan in which silver is bound to a sulfate group of fucoidan and a green tea extract.

[0010] Further, the present invention is an antiviral composition characterized by containing a silver-bound fucoidan in which silver is bound to a sulfate group of fucoidan and a green tea extract.

[0011] Furthermore, the present invention is an antibacterial and / or antiviral product characterized by treating an object to be treated with the above antibacterial composition and / or the above antiviral composition.

[0012] Moreover, the present invention is an antibacterial and / or antiviral method for an object to be treated, characterized by treating the object to be treated with the above antibacterial composition and / or the above antiviral composition.

Effects of the Invention

[0013] The antibacterial composition and antiviral composition of the present invention are highly effective and, since they are derived from natural products, are also highly safe.

[0014] Therefore, the antibacterial composition and antiviral composition of the present invention can be used for preventing infectious diseases by spraying them in places where humans come into contact, treating objects to be treated such as hygiene products with them, spraying them into the throat or nasal cavity, or ingesting them as food or drink.

Brief Description of the Drawings

[0015]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Modes for Carrying Out the Invention

[0016] The antibacterial composition of the present invention contains silver-bound fucoidan (hereinafter sometimes simply referred to as "silver-bound fucoidan") in which silver is bound to the sulfate group of fucoidan and a green tea extract.

[0017] The silver-bound fucoidan used in the antibacterial composition of the present invention is one in which silver is bound to the sulfate group of fucoidan.

[0018] The fucoidan used as the raw material of the above silver-bound fucoidan is a polysaccharide peculiar to brown algae and has sulfated fucose as a constituent sugar. Although brown algae are not particularly limited, examples include Cladosiphon okamuranus, Undaria pinnatifida, Sargassum horneri (Turner) C. Agardh, Laminaria Japonica Areschoug, Fucus distichus, Sargassum fulvellum, etc. Among these, Okamura seaweed fucoidan derived from Cladosiphon okamuranus is preferred. This Okamura seaweed fucoidan has α1,3-linked fucose as the main chain, with 1 molecule of glucuronic acid bound to 4 to 6 molecules of fucose, and also, half of the fucose is sulfated.

[0019] These fucoidans can be used without particular limitation, such as those extracted by the methods described in the literature (M. Nagaoka, et al. : Structural study of fucoidan from Cladosiphon okamuranus TOKIDA. Glycoconjugate Journal 16 : 19-26, 1999) and patents (Patent No. 3920954). Furthermore, the fucoidan may be hydrolyzed with an acid such as hydrochloric acid, or may be purified by, for example, acid washing using an ultrafiltration membrane described in the above patent, electrodialysis, ion exchange column, etc.

[0020] The molecular weight of the fucoidan is not particularly limited, but is, for example, 5 to 250 kDa, preferably 20 to 200 kDa. Note that this molecular weight is a value measured by size exclusion chromatography.

[0021] Such fucoidans may utilize those commercially available from Yakult Pharmaceutical Industry Co., Ltd. under the name "Yakult Fucoidan", etc.

[0022] The method of binding silver to the sulfate group of the above-mentioned fucoidan is not particularly limited as long as it is a method capable of binding silver to the sulfate group of fucoidan. Examples thereof include methods using an ion exchange resin, electrodialysis, or an ultrafiltration membrane.

[0023] The fucoidan used in the above method of binding silver is not particularly limited, and examples thereof include a solution obtained by dissolving fucoidan in water or the like. The content of fucoidan in this solution is not particularly limited, but is, for example, 0.0002 to 10% by mass (hereinafter simply referred to as “%”), preferably 0.1 to 8%. The pH of this solution is not particularly limited, but is 2 to 12, preferably 4 to 10.

[0024] The silver used above is not particularly limited, and examples thereof include a solution obtained by dissolving silver nitrate or the like in water or the like. The content of silver in this solution is not particularly limited, but is, for example, 0.05 μM to 20 M in terms of silver nitrate, preferably 0.6 μM to 15 M. Also, the pH of this solution is not particularly limited, but is 2 to 12, preferably 4 to 10.

[0025] Specifically, the method of binding silver to the sulfate group of fucoidan using an ion exchange resin is as follows. First, a 0.6 μM to 15 M silver nitrate solution is added to a column filled with a cation exchange resin and reacted at room temperature for 0.1 to 2 hours, and then deionized water is passed through the column. On the other hand, fucoidan is dissolved in deionized exchange water to a concentration of 1 to 30 mg / mL, added to the column, and reacted at room temperature for 0.1 to 2 hours. After the reaction, the reaction solution and the column are flushed with 1 to 5 times the volume of deionized water to recover the eluate. Thereby, silver-bound fucoidan is obtained.

[0026] In order to increase the amount of silver bound to the sulfate group of fucoidan, the concentration of the silver solution can be increased, the amount of the cation exchange resin can be increased, the reaction time can be lengthened by passing it through the cation exchange resin multiple times, or stirring can be performed during the reaction.

[0027] After binding silver to the sulfate group of fucoidan as described above, further purification such as dialysis washing, freeze-drying, drying such as spray-drying, chromatography, ultrafiltration, and two-phase partitioning may be performed.

[0028] In the silver-bound fucoidan thus obtained, silver is bound to the sulfate group of fucoidan. The mass ratio of fucoidan to silver is not particularly limited, but is 1:0.0001 or more, preferably 1:0.001 or more, and more preferably 1:0.01 to 0.2. The amount of silver bound to the sulfate group of fucoidan can be measured, for example, by inductively coupled plasma optical emission spectrometry.

[0029] The content of silver-bound fucoidan in the antibacterial composition of the present invention is not particularly limited, but is, for example, 0.0005 to 0.05% by mass, preferably 0.0015 to 0.05% by mass, in terms of silver-bound fucoidan.

[0030] In addition, the green tea extract used in the antibacterial composition of the present invention is obtained by extracting tea leaves of green tea, which is an unfermented tea among teas produced from the leaves of Camellia sinensis (scientific name: Camellia sinensis), with a solvent. Examples of green tea include those produced by the steaming method such as sencha, gyokuro, matcha, and those produced by the pan-firing method such as longjing tea and jasmine tea. Among these green teas, matcha is preferred.

[0031] The solvent used for extracting the above-mentioned green tea is not particularly limited, but examples include water and alcohols such as ethanol. Among these solvents, water is preferred.

[0032] The conditions for extracting green tea with a solvent are not particularly limited. For example, if the solvent is water, the conditions are 80 to 100 °C, preferably 95 to 100 °C, for 10 to 120 minutes, preferably 20 to 40 minutes. The mass ratio of green tea leaves to the solvent during extraction is not particularly limited, but is 1:5 to 50, preferably 1:10 to 30. The green tea extract thus obtained can be used as it is, but it is preferably further dried by removing the solvent according to a conventional method to obtain a dried product.

[0033] In addition, since the above-mentioned green tea extract is commercially available from various companies, they can also be used. Examples of commercially available products of green tea extract include, for example, Sunphenon 90LB-OP (Sun Chemical Corporation) and the like.

[0034] The content of the green tea extract in the antibacterial composition of the present invention is not particularly limited. For example, it is 0.0000005 to 10% in terms of solid content, preferably 0.00001 to 10%, more preferably 0.0005 to 1%, and particularly preferably 0.004 to 0.1%.

[0035] In the antibacterial composition of the present invention, the mass ratio of the silver-bound fucoidan to the green tea extract is not particularly limited. For example, it is 1:0.0005 to 80, preferably 1:0.001 to 50, and preferably 1:0.05 to 30.

[0036] The antibacterial composition of the present invention has an antibacterial effect. Here, the antibacterial effect refers to an antibacterial effect such as a bacteriostatic effect or a bactericidal effect, and particularly refers to a bacteriostatic effect on bacteria. To suppress the growth of bacteria means that the bacteria do not grow or the growth rate is suppressed. Specifically, when 50 μg / mL of silver-bound fucoidan and 200 μg / mL of green tea extract are brought into contact with bacteria, the growth of the number of bacteria is suppressed to 50% or less, preferably 20% or less, compared with the case where neither silver-bound fucoidan nor green tea extract is added, but it is not particularly limited thereto.

[0037] Specifically, the inhibition of bacterial growth refers to the inhibition of the growth of Gram-negative bacteria, Gram-positive bacteria, and fungi. Examples of the above Gram-negative bacteria include Escherichia coli, Salmonella, Vibrio parahaemolyticus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Examples of the above Gram-positive bacteria include Staphylococcus aureus, Clostridium welchii, Legionella, Bacillus cereus, and Bacillus subtilis. Further, examples of the above fungi include Aspergillus versicolor, Penicillium, and Cladosporium. Among these bacteria, Escherichia coli, Salmonella, Staphylococcus aureus, Clostridium welchii, and Staphylococcus epidermidis are preferred, and Escherichia coli, Staphylococcus epidermidis, and Cladosporium are more preferred. Silver-bound fucoidan can inhibit the growth of one or more of these bacteria. Since silver-bound fucoidan is known to have an effect of inhibiting the growth of Salmonella, Staphylococcus aureus, Clostridium welchii, and Staphylococcus epidermidis other than Escherichia coli according to Patent Document 1, the addition of green tea extract can enhance this growth inhibitory effect.

[0038] The antibacterial composition containing the above silver-bound fucoidan and green tea extract has an antiviral effect in addition to the antibacterial effect, and thus can also be used as an antiviral composition. Here, the antiviral effect refers to the virus infection inhibitory effect and / or the virus growth inhibitory effect. Specifically, it refers to inhibiting the adhesion between the virus and the cell to suppress virus infection and inhibiting the growth of the virus.

[0039] Here, inhibiting the adhesion between the virus and the cell means, for example, inhibiting the binding between the virus and the molecules or receptors expressed on the cell surface that are utilized when the virus recognizes the cell, preferably inhibiting the adhesion between the virus and heparan sulfate. Note that heparan sulfate is present on the cell surface. Here, inhibition means reducing the probability of adhesion. Specifically, when 100 μg / mL of silver-bound fucoidan is added in the presence of heparin, which is a type of heparan sulfate, and the spike protein of the virus, the binding between heparin and the spike protein is suppressed to 90% or less compared to the case where no silver-bound fucoidan is added, but it is not particularly limited to this. The virus is not particularly limited as long as it adheres to heparan sulfate on the cell surface, and examples include coronaviruses, herpesviruses, and the like. These antiviral effects are known for silver-bound fucoidan according to Patent Document 1, and these antiviral effects are enhanced by green tea extract.

[0040] In addition, suppressing the growth of the virus means directly acting on the virus to inhibit its growth, preferably meaning that the virus does not grow or the growth rate decreases. Specifically, when 10 μg / mL of silver-bound fucoidan and 0.0064 μg / mL of green tea extract are brought into contact with the virus, the growth of the virus is suppressed to 10% or less compared to the case where no silver-bound fucoidan or green tea extract is added, but it is not particularly limited to this. Examples of the virus include viruses such as coronaviruses, influenza viruses, noroviruses, feline caliciviruses, dengue viruses, herpesviruses, adenoviruses, RS viruses, rhinoviruses, and parainfluenza viruses, and preferably coronaviruses, influenza viruses, noroviruses, herpesviruses, and the like. Silver-bound fucoidan can suppress the growth of one or more of these viruses.

[0041] In the antibacterial composition and antiviral composition of the present invention (hereinafter, these may be collectively referred to as "antibacterial and antiviral composition"), as long as the effects of the present invention are not impaired, for example, water, fragrance, saccharides, ethanol, etc. may be contained.

[0042] Since the antibacterial composition and antiviral composition of the present invention have antibacterial and antiviral effects, they can be used in the same manner as conventional antibacterial and antiviral compositions.

[0043] The dosage form of the antibacterial composition and antiviral composition of the present invention is not particularly limited, and examples include liquid preparations, powders, powders, tablets, granules, capsules, etc. Among these, liquid preparations are preferred.

[0044] More specifically, the antibacterial composition and antiviral composition of the present invention can be sprayed, etc. on places where humans come into contact. The places where humans come into contact are not particularly limited, and examples include doorknobs, tables, chairs, partitions, toys, training equipment, buttons such as those on elevators, etc. The usage amount of the antibacterial composition and antiviral composition of the present invention in this case is not particularly limited, but for example, per 1 cm 2 in terms of silver-bound fucoidan conversion, it is 1 ng to 200 μg, preferably 2 ng to 100 μg. For spraying, a spray or the like can be used. Thereby, the object to be treated can be antibacterial and antiviral.

[0045] In addition, the antibacterial composition and antiviral composition of the present invention can be used, for example, to treat objects to be treated such as hygiene products. The method of treating the antibacterial composition and antiviral composition of the present invention on objects to be treated such as hygiene products is not particularly limited, and examples include methods such as coating and coating. Examples of hygiene products include masks, wet tissues, etc. The treatment amount of the antibacterial composition and antiviral composition of the present invention in this case is not particularly limited, but for example, per 1 cm 2 it is 1 ng to 200 μg, preferably 2 ng to 100 μg. Thereby, the object to be treated will have an antibacterial effect. For treatment, a spray, brush, etc. can be used. Thereby, the object to be treated becomes an antibacterial and antiviral product.

[0046] Furthermore, the antibacterial composition and antiviral composition of the present invention can be used, for example, by spraying them into the throat or nasal cavity, or by bringing them into contact with the pharynx such as in a mouthwash for mice. The amount of the antibacterial composition and antiviral composition of the present invention used in this case is not particularly limited, but for example, it is 0.1 μg to 20 mg, preferably 0.5 μg to 15 mg, more preferably 10 μg to 10 mg, and particularly preferably 100 μg to 5 mg per 1 ml. For spraying, a spray or the like can be used.

[0047] Furthermore, the antibacterial composition and antiviral composition of the present invention can also be used in food and beverages such as lozenges, candies, beverages, and jellies. The amount of the composition of the present invention used in this case is not particularly limited, but for example, it is 0.1 μg to 5 mg, preferably 0.5 μg to 5 mg, more preferably 10 μg to 5 mg, and particularly preferably 100 μg to 5 mg per 1 ml or 1 g. In the case of food and beverages, since the composition of the present invention contains a green tea extract as an active ingredient, it is preferable that the food and beverages do not contain a green tea extract other than that contained in the composition of the present invention, or contain it in an amount that does not affect the effect of the composition of the present invention.

[0048] The antibacterial composition and antiviral composition of the present invention can be used for preventing infectious diseases as described above.

Examples

[0049] Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited to these examples at all.

[0050] Production Example 1 Preparation of silver-bonded fucoidan: A 2M silver nitrate solution was added to a column filled with a cation exchange resin (No. 4, crosslinking degree 8%, 5 - 100 mesh, H form, Fuji Film Wako Pure Chemical Industries, Ltd.). After reacting at room temperature for 1 hour, deionized water was passed through the column. Okinawa mozuku fucoidan (Yakult fucoidan, manufactured by Yakult Pharmaceutical Industry Co., Ltd., molecular weight 79 kDa) was dissolved in deionized water to a concentration of 71.4 mg / mL, added to the column, and passed through twice. After passing through, the eluate and deionized water twice the volume of the column were collected and freeze-dried to obtain a silver-bound fucoidan in which silver was bound to sulfate groups. The silver content in the silver-bound fucoidan was measured by inductively coupled plasma optical emission spectrometry and found to be 0.18 mg per 1 mg.

[0051] Production Example 2 Preparation of green tea extract: To a container, gyokuro tea leaves and 20 times the amount of ion-exchanged water per mass of the gyokuro tea leaves were added. This was heated to boiling and the boiling state was maintained for 30 minutes. After cooling sufficiently, it was filtered through quadruple gauze, and the obtained filtrate was freeze-dried to obtain green tea extract 1.

[0052] Test Example 1 Measurement of Escherichia coli growth inhibitory activity: The green tea extract 1 (dry product) prepared in Production Example 2 was dissolved in Tryptic soy broth (TSB) so that the final concentration was 0.2 mg / mL or 1 mg / mL, and to each of these, a culture solution obtained by culturing Escherichia coli (E. coli K12 strain) in TSB for 24 hours was added at 5%. This was cultured under the condition of 37°C, and the OD600nm at each time was measured to examine the growth inhibitory activity of Escherichia coli. The results are shown in Figure 1.

[0053] From Figure 1, no growth inhibitory activity of Escherichia coli was observed at 0.2 mg / mL for green tea extract 1, and a rather weak activity was observed at 1 mg / mL.

[0054] Test Example 2 Measurement of Escherichia coli growth inhibitory activity: The growth inhibitory activity of Escherichia coli was examined in the same manner as in Test Example 1, except that commercially available green tea extract 2 (Sunphenon 90LB-OP (manufactured by Taiyo Kagaku Co., Ltd.): dried product) was dissolved in TSB so that the final concentration became 4 μg / mL, 20 μg / mL, or 100 μg / mL. The results are shown in Fig. 2.

[0055] From Fig. 2, no growth inhibitory activity of Escherichia coli was observed at 4 μg / mL and 20 μg / mL of green tea extract 2, and a rather weak activity was observed at 100 μg / mL.

[0056] Test Example 3 Measurement of growth inhibitory activity against Escherichia coli: The growth inhibitory activity of Escherichia coli was examined in the same manner as in Test Example 1, except that the silver-bound fucoidan prepared in Production Example 1 was dissolved in TSB so that the final concentration became 50 μg / mL and the green tea extract 1 prepared in Production Example 2 was dissolved in TSB so that the final concentration became 0.2 mg / mL or 1 mg / mL. Also, for comparison, the growth inhibitory activity of Escherichia coli after 14 hours was examined using silver-bound fucoidan or green tea extract 1 at the same final concentration, respectively. The results are shown in Fig. 3.

[0057] From Fig. 3, when 0.2 mg / mL of green tea extract 1, which showed no growth inhibitory activity against Escherichia coli alone, or 1 mg / mL of green tea extract 1, which showed rather weak growth inhibitory activity against Escherichia coli, was combined with 50 μg / mL of silver-bound fucoidan, which showed growth inhibitory activity against Escherichia coli, it was found that the growth inhibitory activity of silver-bound fucoidan against Escherichia coli was significantly enhanced. In this system, compared with 50 μg / mL of silver-bound fucoidan alone, the addition of green tea extract suppressed the growth of the number of bacteria by 25 to 30%.

[0058] Test Example 4 Measurement of growth inhibitory activity against Escherichia coli: The inhibitory activity of silver-bound fucoidan prepared in Production Example 1 on the growth of E. coli was examined in the same manner as in Test Example 1, except that the final concentration of silver-bound fucoidan was adjusted to 50 μg / mL and the final concentration of commercially available green tea extract 2 was adjusted to 4 μg / mL, 20 μg / mL, or 100 μg / mL by dissolving in TSB. Also, for comparison, the inhibitory activity of silver-bound fucoidan or green tea extract 2 on the growth of E. coli after 14 hours was examined using the same final concentration of each. These results are shown in Fig. 4.

[0059] From Fig. 4, it was found that when 50 μg / mL of silver-bound fucoidan, which showed inhibitory activity against E. coli, was combined with 4 μg / mL or 20 μg / mL of green tea extract 2, which showed no inhibitory activity against E. coli alone, or 100 μg / mL of green tea extract 2, which showed a considerably weak inhibitory activity against E. coli, the inhibitory activity of silver-bound fucoidan against E. coli was significantly enhanced.

[0060] Test Example 5 Measurement of inhibitory activity on E. coli growth: The inhibitory activity of E. coli growth was examined in the same manner as in Test Example 1, except that the final concentration of commercially available green tea extract 2 was adjusted to 10 μg / mL, 20 μg / mL, 40 μg / mL, or 80 μg / mL by dissolving in TSB. These results are shown in Fig. 5.

[0061] From Fig. 5, no inhibitory activity on E. coli growth was observed at 10 μg / mL and 20 μg / mL of green tea extract 2, and a considerably weak activity was observed at 40 μg / mL and 80 μg / mL.

[0062] Test Example 6 Measurement of inhibitory activity on E. coli growth: The inhibitory activity of E. coli growth was examined in the same manner as in Test Example 1, except that the final concentration of silver-bound fucoidan prepared in Production Example 1 was adjusted to 60 μg / mL and the final concentration of commercially available green tea extract 2 was adjusted to 10 μg / mL, 20 μg / mL, 40 μg / mL, or 80 μg / mL by dissolving in TSB. Also, for comparison, the inhibitory activity of silver-bound fucoidan or green tea extract 2 on the growth of E. coli after 14 hours was examined using the same final concentration of each. These results are shown in Fig. 6.

[0063] As shown in Figure 6, when the green tea extract 2 at 10 μg / mL or 20 μg / mL, which showed no inhibitory activity against the growth of Escherichia coli alone, or at 40 μg / mL or 80 μg / mL, which showed a rather weak inhibitory activity against the growth of Escherichia coli, was combined with the silver-bound fucoidan at 60 μg / mL, which showed an inhibitory activity against the growth of Escherichia coli, it was found that the inhibitory activity of the silver-bound fucoidan against the growth of Escherichia coli was significantly enhanced.

[0064] Test Example 7 Measurement of inhibitory activity against the growth of Escherichia coli: The inhibitory activity against the growth of Escherichia coli was examined in the same manner as in Test Example 1, except that the final concentration of the silver-bound fucoidan prepared in Production Example 1 was dissolved in TSB to 70 μg / mL and the final concentration of the commercially available green tea extract 2 was dissolved in TSB to 10 μg / mL, 20 μg / mL, 40 μg / mL or 80 μg / mL. Also, for comparison, the inhibitory activity against the growth of Escherichia coli after 16 hours was examined using the silver-bound fucoidan or the green tea extract 2 at the same final concentration. These results are shown in Figure 7.

[0065] As shown in Figure 7, when the green tea extract 2 at 10 μg / mL or 20 μg / mL, which showed no inhibitory activity against the growth of Escherichia coli alone, or at 40 μg / mL or 80 μg / mL, which showed a rather weak inhibitory activity against the growth of Escherichia coli, was combined with the silver-bound fucoidan at 70 μg / mL, which showed an inhibitory activity against the growth of Escherichia coli, it was found that the inhibitory activity of the silver-bound fucoidan against the growth of Escherichia coli was significantly enhanced.

[0066] Test Example 8 Measurement of inhibitory activity against cell infection of SARS2-CoV-2: (1) Preparation of test substances The commercially available green tea extract 2 was diluted to 0.0064 μg / mL, 0.032 μg / mL, and 0.16 μg / mL. The silver-bound fucoidan prepared in Production Example 1 was prepared to 10 μg / mL with Milli Q water. After filtering this with a 0.45 μm filter, it was used for the experiment.

[0067] (2) Evaluation of virus cell infection using luciferase luminescence A pseudotyped virus (SARS2-pv) with the spike protein of SARS-CoV-2 coated on vesicular stomatitis virus (VSV) lacking the gene encoding the envelope protein due to the insertion of the luciferase gene was prepared according to a previous report (Tani et al. Virol J (2021) 18:16). An angiotensin-converting enzyme 2 (ACE2) stable expression cell line was seeded at 2×10 4 cells / well in a 96-well White / Clear Bottom Plate (Thermo Fisher Scientific). The next day, 10 μL of the test substance and 10 μL of SARS2-pv were mixed, reacted at room temperature for 5 minutes, and then added to the cell culture supernatant. After culturing for 24 hours, 20 μL / well of Picagene BrillianStar-LT luminescence reagent (Toyobo) was added, allowed to stand for 5 minutes, and then luminescence by luciferase was measured using a Spectramax M5e (Molecular Devices). The cell infection inhibitory effect of SARS2-pv was shown as a percentage when the luminescence intensity of the well added by mixing SARS2-pv and the solvent (Milli Q water) was set to 100% (Figure 8).

[0068] (3) Cell viability assay (MTS) The day after seeding cells at 1 - 2×10 4 cells / well in a 96-well plate, 10 μL of the test substance was added. After culturing for 24 hours, 10 μL / well of CellTiter 96 AQueous One Solution Reagent of the CellTiter AQueous One Solution Cell Proliferation Assay (Promega) was added, reacted in a 37°C CO2 incubator for 1 hour, and then the absorbance at 490 nm was measured. The well with the test substance added only to the medium was used as the background, and the background was subtracted for each test substance. The value of the MTS assay was shown as a percentage when the value of the well added with the solvent was set to 100% (not shown).

[0069] As shown in Fig. 8, when 10 μg / mL of silver-bound fucoidan having an inhibitory effect on virus cell infection was combined with 0.0064 μg to 0.16 μg / mL having a considerably lower inhibitory effect on virus cell infection, it was found that the growth inhibitory activity of Escherichia coli by silver-bound fucoidan was significantly enhanced. Also, within this range, no cytotoxicity was observed. In this system, by adding green tea extract, the growth of the virus was suppressed to 15% or less even when compared with silver-bound fucoidan alone.

[0070] Example 1 Production of antibacterial and antiviral composition: An antibacterial and antiviral composition was produced by mixing the following components. (Component) Silver-bound fucoidan (prepared in Production Example 1) 0.01% Green tea extract 2 0.008% Water 99.982%

[0071] This antibacterial and antiviral composition was sprayed onto a doorknob with a spray and dried.

[0072] Example 2 Production of antibacterial and antiviral composition: An antibacterial and antiviral composition was produced by mixing the following components. (Component) Silver-bound fucoidan (prepared in Production Example 1) 0.002% Green tea extract 2 0.002% Water 39.996% Ethanol 60.0%

[0073] This antibacterial and antiviral composition was evenly sprayed onto a mask with a spray and dried to produce an antibacterial and antiviral mask.

[0074] Example 3 Production of antibacterial and antiviral composition: An antibacterial and antiviral composition was produced by mixing the following components. (Component) Silver-bonded fucoidan (prepared in Production Example 1) 0.01% Green tea extract 2 0.008% Water 95.972% Maltitol 4.00% Flavor 0.01%

[0075] This antibacterial and antiviral composition was sprayed into the throat and nasal cavity with a spray.

[0076] Example 4 Production of a beverage containing an antibacterial and antiviral composition: Each component of the following formulation was mixed to produce a beverage containing an antibacterial and antiviral composition. (Component) Silver-bonded fucoidan (prepared in Production Example 1) 0.01% Green tea extract 2 0.005% Job's tears tea extract 99.985%

Industrial Applicability

[0077] The antibacterial composition and antiviral composition of the present invention can be used for preventing infectious diseases.

Claims

1. An antibacterial composition characterized by containing a silver-bonded fucoidan in which silver is bonded to a sulfate group of fucoidan and a green tea extract.

2. The antibacterial composition according to Claim 1, wherein the fucoidan is Okinawa mozuku fucoidan.

3. The antibacterial composition according to Claim 1, which inhibits the growth of Gram-negative bacteria, Gram-positive bacteria or fungi.

4. The antibacterial composition according to Claim 1, wherein the mass ratio of fucoidan to silver is 1:0.0001 or more.

5. The antibacterial composition according to Claim 1, wherein the content of the silver-bonded fucoidan is 0.0005 to 0.05% by mass.

6. An antiviral composition characterized by containing a silver-bonded fucoidan in which silver is bonded to a sulfate group of fucoidan and a green tea extract.

7. The antiviral composition according to Claim 6, wherein the fucoidan is Okinawa mozuku fucoidan.

8. The antiviral composition according to Claim 6, which inhibits the adhesion of a virus to heparan sulfate.

9. The antiviral composition according to Claim 6, which inhibits the growth of a virus.

10. The antiviral composition according to Claim 6, wherein the mass ratio of fucoidan to silver is 1:0.0001 or more.

11. The antiviral composition according to Claim 6, wherein the content of the silver-bonded fucoidan is 0.0005 to 0.05% by mass.

12. An antibacterial and / or antiviral product, characterized in that the antibacterial composition according to any one of Claims 1 to 5 and / or the antiviral composition according to any one of Claims 6 to 11 is used to treat an object to be treated.

13. A method for antibacterial and / or antiviral treatment of an object to be treated, characterized in that the antibacterial composition according to any one of Claims 1 to 5 and / or the antiviral composition according to any one of Claims 6 to 11 is used to treat the object to be treated.

Images